Human EML4-ALK-G1202R/L1198F Stable Cell Line - Ba/F3

Alectinib has emerged as a potent treatment option, yet many patients experience relapse due to secondary mutations in the ALK gene, such as G1202R and I1171N. These mutations present a challenge, as they confer resistance to first-line therapies. In recent studies, it was demonstrated that several lorlatinib-resistant ALK-compound mutants, including those with G1202R mutations, exhibit higher resistance levels than their single-mutant counterparts. Importantly, some of these compound mutants respond favorably to earlier generation ALK tyrosine kinase inhibitors (TKIs), such as crizotinib and alectinib, suggesting potential therapeutic strategies for managing resistance in clinical settings.

Figure 1. The researchers employed ENU mutagenesis screening to identify ceritinib- or lorlatinib-resistant ALK compound mutations in Ba/F3 cells, aiming to uncover therapeutic strategies for overcoming resistance in ALK-mutated NSCLC. (Okada K, et al., 2019)

The Human EML4-ALK-G1202R/L1198F Stable Cell Line from Creative Biogene is designed for researchers exploring these complex mutations and their implications for treatment. This cell line provides a valuable tool for studying drug sensitivity and resistance mechanisms in ALK-mutated NSCLC.